arrow
P

Philip C. Schouten

Netherlands Cancer Institute
H指数:21
被引数:2,949

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers

长链非编码RNA作为同源重组缺陷和PARP抑制剂敏感性的生物标志物,在高级别浆液性卵巢癌中的应用

2025-10-010
OA
PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)
2024-04-050
PRE
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status

根据BRCA1状态的年轻,淋巴结阴性,化疗初治,三阴性乳腺癌患者的长期结果

2024-01-090
OAAI
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial

根据HRD/BRCAwt基因组图谱的HIPEC在III期卵巢癌中的作用: 来自III期OVHIPEC试验的结果

2022-06-0430
OA
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients

早期三阴性乳腺癌患者中含卡培他滨的辅助化疗获益和同源重组缺陷

2022-02-0512
OA
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial (vol 25, pg 920, 2019)
2019-06-1712
OAAI
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

转移性三阴性乳腺癌的免疫诱导策略可增强对PD-1阻滞的敏感性: TONIC试验

2019-05-13643
PREAI
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
2017-08-2561
OAAI
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

在GAIN随机对照试验中,BRCA1-like特征与非清髓性强化化疗的生存获益无显著相关性

2017-08-182
PREAI
PD-L1 positive tumor-infiltrating lymphocytes and mutational load in breast cancer
2017-07-010
PRE
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
2016-01-05143
OAAI